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Abstract 
Purpose: To evaluate the effect of increasing the treatment zone diameter through a larger optical zone 
(OZ) lens in orthokeratology. 
Methods: This study involved the evaluation of 12 eyes of 6 patients with low to moderate myopia and/or 
astigmatism. Subjects wore BE Retainer lenses (6.0 mm optic zone) overnight and were evaluated the 
following morning. Successful subjects then wore these lenses consecutively for 1 week and 1 month 
from the time of the initial dispensing. The second phase of the study involved switching the subjects 
from initial phase to larger B zone lens (6.7 mm optic zone). Again, 1 day, 1 week, and 1 month 
evaluations were conducted. On each follow up visit, subjective questionnaires, case histories, visual 
acuities, refractions, biomicroscopy, and corneal topographies were performed. 
Results: Most subjects reached an uncorrected visual acuity (UCVA) of either 20/20 or 20/16 with both 
optical zone lenses. No significant improvements or deteriorations in visual acuity were noted with the 
different optical zone treatment diameters. Refractive error changes also showed similar results between 
the right and left eyes for each optical zone lens diameter with a mean change of 2.26 0 (R) and 1.94 0 (L) 
with the 6.0 mm OZ lens and 1.92 0 (R) and 1.81 0 (L) with the 6.7 mm OZ lens. The final average 
spherical equivalent refractive error was +0.63 OS (R) and +0.60 OS (L) for the 6.0 mm OZ and +0.29 OS 
(R) and +0.60 OS (L) for the 6.7 mm OZ lens. The subjects did not have significant changes in the 
treatment zone diameters between the 6.0 mm OZ and 6. 7 mm OZ lenses with a mean average increase 
of 0.195 mm 00 and 0.162 mm OS. Most subjects had a slightly progressive decrease in nighttime glare 
from pretreatment to post-treatment with a both optical zone lenses. 
Conclusion: An increase in optical zone diameter lens did not significantly increase the treatment zone 
diameter and did not adversely affect uncorrected visual acuity. There was a small decrease in the effects 
of nighttime glare with the larger optical zone lens. 
Degree Type 
Thesis 
Degree Name 
Master of Science in Vision Science 
Committee Chair 
Patrick Caroline 
Subject Categories 
Optometry 
This thesis is available at CommonKnowledge: https://commons.pacificu.edu/opt/1531 
Copyright and terms of use 
If you have downloaded this document directly from the web or from CommonKnowledge, see 
the “Rights” section on the previous page for the terms of use. 
If you have received this document through an interlibrary loan/document delivery service, the 
following terms of use apply: 
Copyright in this work is held by the author(s). You may download or print any portion of this 
document for personal use only, or for any use that is allowed by fair use (Title 17, §107 U.S.C.). 
Except for personal or fair use, you or your borrowing library may not reproduce, remix, 
republish, post, transmit, or distribute this document, or any portion thereof, without the 
permission of the copyright owner. [Note: If this document is licensed under a Creative 
Commons license (see “Rights” on the previous page) which allows broader usage rights, your 
use is governed by the terms of that license.] 
Inquiries regarding further use of these materials should be addressed to: CommonKnowledge 
Rights, Pacific University Library, 2043 College Way, Forest Grove, OR 97116, (503) 352-7209. 
Email inquiries may be directed to:.copyright@pacificu.edu 
THE EFFECT OF INCREASING THE TREATMENT ZONE DIAMETER 
THROUGH A LARGER OPTICAL ZONE LENS IN ORTHOKERATOLOGY 
BY 
CHRISTOPHER JOHNSON 
CHRISTOPHER KELLY 
DENIS KIM 
A thesis submitted to the faculty of the 
College of Optometry 
Pacific University 
Forest Grove, Oregon 
for the degree of 
Doctor of Optometry 
May 2006 
Advisor: 
Patrick Caroline, C.O.T., F.A.A.O. 
PACIFIC lJN~V~~rfY L~?•.lff 
FGREfl" ~~iii. ~ililN 
Christopher Johnson 
Christopher Kelly 
Denis Kim 
BIOGRAPHY 
Christopher Johnson 
Christopher Johnson was born and raised in Edmonton, Alberta. He 
received his Bachelor of Science degree from the University of Alberta. Upon 
graduation and licensure, he plans on practicing in Calgary, Alberta 
Christopher Kelly 
Chris Kelly was born in Fargo, North Dakota. He spent most of his 
younger years between Minnesota and Alaska, but moved to Oregon in high 
school. He received his Bachelor of Science degree from the University of 
Oregon. Upon completion of the Doctor of Optometry program from Pacific 
University he will be commissioned as a Captain in the U.S. Army, where he will 
serve as an Army Optometrist for his fellow soldiers for a minimum of three 
years. After completion of his tour in the Army he plans on practicing in Oregon 
or Minnesota, where most of his family resides. 
Denis Kim 
Denis Kim was born in Grande Cache, Alberta Canada but spent most of 
his life in Edmonton, Alberta. He completed undergraduate work at the University 
of Alberta and upon graduation and licensure, he plans on practicing in the 
Pacific Northwest or in British Columbia. 
ABSTRACT 
Purpose: To evaluate the effect of increasing the treatment zone diameter 
through a larger optical zone (OZ) lens in orthokeratology. 
Methods: This study involved the evaluation of 12 eyes of 6 patients with low to 
moderate myopia and/or astigmatism. Subjects wore BE Retainer lenses (6.0 
mm optic zone) overnight and were evaluated the following morning. Successful 
subjects then wore these lenses consecutively for 1 week and 1 month from the 
time of the initial dispensing. The second phase of the study involved switching 
the subjects from initial phase to larger B zone lens (6.7 mm optic zone). Again, 1 
day, 1 week, and 1 month evaluations were conducted. On each follow up visit, 
subjective questionnaires, case histories, visual acuities, refractions, 
biomicroscopy, and corneal topographies were performed. 
Results: Most subjects reached an uncorrected visual acuity (UCVA) of either 
20/20 or 20/16 with both optical zone lenses. No significant improvements or 
deteriorations in visual acuity were noted with the different optical zone treatment 
diameters. Refractive error changes also showed similar results between the 
right and left eyes for each optical zone lens diameter with a mean change of 
2.26 0 (R) and 1.94 0 (L) with the 6.0 mm OZ lens and 1.92 0 (R) and 1.81 0 (L) 
with the 6.7 mm OZ lens. The final average spherical equivalent refractive error 
was +0.63 OS (R) and +0.60 OS (L) for the 6.0 mm OZ and +0.29 OS (R) and 
+0.60 OS (L) for the 6.7 mm OZ lens. The subjects did not have significant 
changes in the treatment zone diameters between the 6.0 mm OZ and 6. 7 mm 
OZ lenses with a mean average increase of 0.195 mm 00 and 0.162 mm OS. 
Most subjects had a slightly progressive decrease in nighttime glare from pre-
treatment to post-treatment with a both optical zone lenses. 
Conclusion: An increase in optical zone diameter lens did not significantly 
increase the treatment zone diameter and did not adversely affect uncorrected 
visual acuity. There was a small decrease in the effects of nighttime glare with 
the larger optical zone lens. 
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INTRODUCTION 
Orthokeratology (ortho-k) is a non-invasive, reversible procedure that 
allows for a temporary correction of myopia with moderate amounts of 
astigmatism. This procedure involves wearing gas-permeable lenses overnight 
that flatten the central cornea during sleep, resulting in clear uncorrected visual 
acuity (UCVA) when the lenses are removed upon waking. Vision is considerably 
improved after just one night of wear and most patients can go through the day 
wearing no correction. However, the effects of ortho-k are temporary and usually 
last up to one to two days. Therefore, patients must wear a retainer lens to 
maintain the desired correction and a minimal wear time is established to 
maintain the ideal corneal shape and visual function. 
Orthokeratology is viable, non-invasive, reversible alternative to refractive 
surgery, such as LASIK, and offers freedom from glasses and the inconvenience 
of wearing contact lenses during the day. It can be performed on virtually anyone 
as long as there are no ocular or systemic contraindications to contact lenses. 
Ortho-k holds particular appeal for athletes, those who work in dusty, dirty 
environments, and/or occupations, such as pilots, police officers, or fire fighters, 
where regular contact lens wear may be contraindicated. Because this procedure 
offers similar benefits to LASIK, it is also a viable option to adolescents and teens 
that are not eligible for refractive eye surgery. Furthermore, it eliminates any 
apprehension towards the complications and permanency of surgery. It can also 
be a good option for patients suffering from dry eye, which is commonly 
exacerbated by refractive laser surgery, and irritation associated with contact 
lens wear from dust and pollutants. 
In the late 1950's and early 1960's, optometrists noticed that patients, who 
were fitted with contact lenses flatter than k, were less myopic after lens removal. 
Consequently, orthokeratology techniques were developed using flat lenses with 
large optical zones. The choice of material then was polymethyl-methacrylate 
(PMMA) and thus required long adjustment periods. Moreover, these plastic 
lenses did not allow passage of oxygen to the cornea. The subsequent 
development of rigid gas permeable (RGP) lens materials markedly improved the 
safety of lens wear as these materials allow oxygen to pass through to the 
cornea. The RGP lenses also increase the performance of orthokeratology as the 
ability to use larger overall diameters allow for a greater centration. 
Our understanding and knowledge of orthokeratology has significantly 
increased, resulting in the development of modern corneal refractive therapy 
(CRT) and vision shaping treatment (VST). The Paragon CRT, and recently FDA 
approved VST by Bausch & Lomb, are the result of ongoing research and 
technological advancements in corneal reshaping and lens materials. According 
to Patrick Caroline, FCLSA, FAAO, five technological advances have enabled 
orthokeratology to achieve a greater success rate: 
1) Advances in multicurve GP lenses specifically designed to facilitate the 
safe redistribution of corneal tissue while sleeping. 
2) Advances in computer-controlled lathing technology, allowing complex 
lens designs to be consistently fabricated and with seamless polished 
surfaces and on a tolerance level measured in microns. 
3) The development of stable wettable, high Dk materials that can be 
safely worn overnight. 
4) Advances in computerized corneal mapping techniques providing more 
precise fitting and follow-up of patients. 
5) A greater understanding of how corneal reshaping works and the 
tissues involved in the process. 
The Food and Drug Administration granted overnight wear approval to a 
Paragon Vision's CRT in June 2002 and Bausch & Lomb's VST in late 2004. 
CRT is already widely available and according to www.allaboutvision.com, about 
2000 practitioners are expected to be fitting VST by the end of 2005. 
Many patients that undergo orthokeratology complain of nighttime glare. 
Most of this can be attributed to the fact that with standard ortho-k lenses, the 
treatment zone (area of corneal flattening) is 5.0mm in diameter. If the pupil 
dilates to more than 5.0mm at night for example, the result is glare. Currently, 
standard ortho-k lenses have an optical zone of 6.0mm, leading to a 5.0mm 
treatment zone. The main objective of this study was to determine whether an 
increase in the treatment zone from a S.Omm to 5.7mm with a 6.0mm and 6.7mm 
optical zone lens respectively, would decrease glare. We hypothesize that 
increasing the treatment zone will not only significantly reduce complaints of 
nighttime glare and not adversely affect UCVA, but it will decrease the gap with 
corrective laser surgery, wh ich has a 6.0mm treatment zone. This will ultimately 
make orthokeratology a more viable option to a larger segment of the population. 
METHODS 
In this study, we used the BE Retainer lens design which is one of the 
designs utilized with Bausch & Lomb's Vision Shaping Treatment. This gas-
permeable lens has a unique back surface geometry but is not a true reverse 
geometry or four-curve retainer design. According to Dr. John Mountford and Dr. 
Don Noack, the developers of the BE Retainer lens, it is a platform that produces 
the required tear layer profile for an individual corneal shape that produces 
squeeze film forces that effectively control epithelial redistribution causing the 
desired refractive change. It is custom fit to the patient's specific corneal shape, 
which is determined utilizing topographical information. They have termed this 
therapy Optimal Orthokeratology (OOK). This therapy allows the practitioner to 
be in total control of the fitting process through the use of BE software, which 
allows for trial retainer determination, problem solving, custom retainer 
construction , predictions of the amount of refractive change possible, and 
potential treatment zone size. A patient's potential for OOK is determined from 
four topographical components: 
1) Sagittal height: the height in microns of the cornea over a specific cord 
diameter so that a fit to a desired apical clearance in order to achieve the 
correct squeeze film pressure. 
2) Eccentricity Value (E-value): the "rate of flattening" of the cornea form the 
apex to the periphery; indicates a patient's potential for OOK; the lower 
the e-value, the lower the potential for OOK and vice versa. 
3) Apical radius (Ro): the calculation of the radius at the apex of the cornea. 
4) Required refractive change. 
The program also determines the potential success of OOK for the patient by 
comparing the refractive potential of the cornea from the apical radius and 
sagittal height with the required refractive change. Once the patient's data is 
entered into the BE program and the desired refractive change is determined, the 
patient's required custom ordered BE Retainer and diagnostic trial retainer in the 
standard BE Retainer set are calculated. This trial retainer is then worn overnight 
and follow-up examinations are performed the next morning. This involves an 
evaluation of the retainer lens positioning and any notable physiological response 
to the therapy. Upon removal of the retainer lens, a subjective over-refraction is 
performed and topographical maps are taken. These maps are evaluated (as 
axial, tangential, and subtractive/difference maps) and the measured responses 
to the therapy are determined. The three main responses are: 
1) Bulls-eye: The ideal corneal shape change for accurate refractive 
response. 
2) Smiley Face: The negative corneal response to a flat fitting BE Retainer 
OOK. 
3) Central Island: The negative corneal response to a steep fitting BE 
Retainer OOK. 
Depending on the response, final retainer parameters are determined and 
ordered or retrials are performed after the cornea returns to its normal curvature. 
This study involved the evaluation of 12 subjects from the class of 2007 at Pacific 
University College of Optometry, approximately 18 to 30 years of age. All 
subjects were required to be low to moderate myopes and/or astigmats 
(approximately 0.75 to 4.00 diopters spherical correction of myopia and 1.50 
diopters or less correction of astigmatism). Subjects were screened for ocular 
health based on systemic health history, anterior segment evaluation, Goldman 
applanation tonometry, corneal topographical mapping, habitual visual acuities, 
and baseline manifest dry refractions. Those whose ocular health were 
compromised and/or did not meet the refractive error criteria were excluded from 
the study. Informed consent was obtained from all participants outlining the 
nature of the study, procedures, and proper lens care regimen. Moreover, 
subjects were asked to complete a subjective questionnaire on glare. From the 
initial twelve applicants, six did not achieve an optimal lens fit and/or had difficulty 
with gas-permeable lens wear hindering participation in the study. Therefore, six 
subjects completed the study. 
Prior to dispensing the trial lenses for overnight wear, subjects were 
supplied with an adequate amount of Advanced Medical Optics (AMO) cleaning 
and conditioning gas-permeable lens solutions and educated on proper lens care 
and insertion/removal techniques. They were also instructed to wear the lenses 
for a minimum of six hours at night. Following an evaluation of overnight trial 
lenses the following morning, standard custom BE retainer lenses (6.0 mm optic 
zone) were ordered from Precision Technologies in Vancouver, British Columbia. 
Subjects were again asked to wear the lenses overnight and to return to clinic the 
next morning for an evaluation. If these subjects were successful, they were 
asked to wear the lenses consecutively for 1 week and 1 month from the 
dispensed time of the custom lenses. The second phase of the study involved 
switching successful subjects from initial phase to larger B zone lens (6.7 mm 
optic zone) after allowing the corneas to normalize for 1 week. Again, 1 day, 1 
week, and 1 month evaluations were conducted once these new lenses were 
dispensed. 
Follow up visits consisted of the following procedures: 
1) Subjective questionnaire: to assess glare with questions about visual 
disturbances during night driving and with bright lights. 
2) Case history: to determine the compliance of the lens wear regimen 
and to determine any symptoms of lens wear. 
3) Visual Acuity: distance monocular uncorrected visual acuities were 
tested. 
4) Refraction: a manifest dry refraction was performed upon removal of 
the lens after visual acuity assessment. 
5) Biomicroscopy: the ocular health was evaluated for fluorescein staining 
of the cornea and any other complications related to contact lens wear. 
6) Topography: the topographical maps were taken with the Medmont 
E300 topographer to monitor the treatment zones. Analysis with 
subtractive/difference display maps was also performed to compare 
the base line maps to the 1 day, 1 week, and 1-month topographical 
maps with both optical zone lenses. 
RESULTS 
From the data collected, we analyzed four criteria from the different optical 
zone treatment lenses: uncorrected visual acuity, refractive error change, 
treatment zone diameter, and glare responses. 
Most subjects achieved similar final visual acuities in both eyes with the 6.0 
mm OZ and 6. 7 mm OZ lenses after 1 month of lens wear reaching an UCVA of 
either 20/20 or 20/16. No significant improvements or deteriorations in visual 
acuity were noted with the different optical zone treatment diameters. However, 
one subject did not achieve a 20/20 or 20/16 UCVA, achieving a UCVA of 20/25 
OU with the 6.0 mm OZ lens that deteriorated to a 20/40 visual acuity OU with 
the 6.7 mm OZ lens. This subject also had complaints of headaches, visual 
distortion, and glare with both lenses. The remaining subjects did not have any of 
the previously mentioned vision concerns during the study (Table I, Figure 1). 
The refractive error changes showed similar results between the right and left 
eyes for each optical zone lens. An average refractive error change was 2.26 0 
(R) and 1.94 0 (L) with the 6.0 mm OZ lens and 1.92 0 (R) and 1.81 D (L) with 
the 6.7 mm OZ lens. Moreover, the final average spherical equivalent refractive 
error was +0.63 OS (R) and +0.60 OS (L) for the 6.0 mm OZ and +0.29 DS (R) 
and +0.60 DS (L) for the 6.7 mm OZ lens. Five subjects were mild to moderately 
overcorrected while one subject was moderately under-corrected (Table II). In 
general, there was a larger change in refractive error with the 6.0 mm OZ lens 
versus the 6.7 mm OZ lens (Figure 2). 
Overall, the subjects did not have significant changes in treatment zone 
diameters between the 6.0 mm OZ and 6.7 mm OZ lenses despite the increase 
in optical zone (Table Ill, Figure 3}. Of the 12 eyes that were treated, 7 eyes had 
and increase in the treatment zone diameter, while unpredictably 5 eyes had a 
decrease in the treatment diameter. Overall, there was a 0.195 mm increase in 
treatment zone diameter OD and a 0.162 mm increase OS. We also noted that 
the largest change observed from a 6.0 mm OZ treatment lens to a 6. 7 mm OZ 
treatment lens was 0.93 mm while the largest decrease was 0.43 mm. 
All of our subjects were asked about glare and halos during night driving and with 
bright lights pre-treatment and 1 month post-treatment with the 6.0 mm OZ and 
6.7 mm OZ lenses. Glare assessment was based on a subjective questionnaire 
with numeric values assigned to the degree of perceived visual disturbance (0 = 
no glare, 2 = occasionally, 3 = half of the time, 4 = most of the time, 5= all of the 
time) . Most subjects had a slightly progressive decrease in glare and halos 
effects from pre-treatment to post-treatment with the 6.0 mm OZ and 6.7 mm OZ 
lens (Table IV, Figure 4). One subject however, noticed a slight increase in visual 
disturbance wh ile the final results for two of the subjects were inconclusive. 
DISCUSSION 
This purpose of this study was to observe the effects of nighttime glare 
and vision with an increase in the treatment zone diameter. We hypothesized 
that an increase in the treatment zone from a 6.0mm to 6.7mm optical zone lens 
would decrease glare and not adversely affect uncorrected visual acuity, allowing 
orthokeratology to be a viable, non-invasive, alternative option for refractive 
surgery and for those with glare problems. 
Most subjects achieved clear UCVA with both the standard 6.0 mm OZ 
and the larger 6.7 mm OZ lens without significant differences between the final 
uncorrected visual acuities. This increase in optical zone did not seem to 
adversely affect the UCVA, and treatment zone diameters with both lenses 
developed good bull's-eye pattern topographical maps for each subject. This 
indicates that both optical zone lenses may be good options for orthokeratology 
patients. Most of the subjects in this study however, had mild amounts of myopia 
and astigmatism and subsequently developed good final visual acuities with 
minimal overcorrected refractive errors after treatment with both lenses. On the 
other hand, one subject had a moderate amount of myopia and notably, did not 
achieve 20/20 vision with the larger OZ lens resulting in even worse UCV A. This 
subject was also moderately under corrected and had the most complaints of 
glare and halo effects from the treatment. With larger refractive errors, it may be 
more challenging to achieve clear UCVA and treatment results can be more 
variable. This may account for this subject not being able to achieve 20/20 UCVA 
and visual disturbances with glare and halos. Further investigations are needed 
with a larger patient population of moderate to moderately high myopes to fully 
assess the effects of glare and UCVA with an increase in treatment zone 
diameter. 
We predicted that increasing the treatment zone diameter would decrease 
the effects of nighttime glare. Unexpectedly, there was not a significant increase 
in the treatment zone diameters from the 6.0 mm OZ to the 6.7 mm OZ lens, with 
some eyes even showing a decrease in the treatment zone diameter with the 
larger OZ. It was therefore difficult to assess the effects of glare and halos 
subjectively, without a significant change between the treatment zone diameters. 
The majority of the subjects did however show a small decrease in visual 
disturbance despite this small change. Patient compliance may account for this 
small increase as any variability in wearing schedules of the participants can 
result in unreliable data between the two treatment zone diameters. Moreover, 
pupillary diameter in photopic and scotopic conditions was not considered in this 
study. According to Macsai et al., pupil size is arguably the most important 
predictor of night-vision disturbances and future quantification may provide for a 
more accurate assessment of glare. Those subjects with small pupillary 
diameters may not appreciate glare effects when moving from a smaller to larger 
optical zone diameter lens while those individuals with larger pupillary diameters 
may experience glare effects in scotopic conditions when the pupillary diameter 
exceeds the treatment zone diameter. An objective measurement of glare should 
also be considered in future studies for a more comprehensive investigation of 
the effects of glare with a larger treatment zone diameter. Another consideration 
may include a larger optical zone (>6. 7 mm OZ) to better discriminate the effects 
of glare with different OZ lenses. 
Similar studies on the effects of increased treatment zone diameter and 
glare in refractive laser surgery have been studied in the past and are currently 
ongoing. Macsai et al. evaluated the effect of expanding the treatment zone of 
the Nidek EC-5000 laser on postoperative visual acuity as well as night glare and 
halos after laser in situ keratomileusis (LASIK) using 4 ablation zone diameters. 
They used a 6.5 mm optical zone with a transition zone 1.0 mm larger than the 
pupil under scotopic conditions (7.5, 8.0, 8.5, or 9.0 mm) and queried about glare 
and halos preoperatively and 3 months postoperatively using a subjective 
questionnaire. They found that the use of a peripheral transition zone 1.0 mm 
larger than the pupil under scotopic conditions resulted in a low incidence of 
glare and halos postoperatively and did not adversely affect visual acuity. 
Our investigation demonstrated that an increase in treatment zone 
diameter did not significantly decrease glare and that it did not adversely affect 
uncorrected visual acuity. Other studies with refractive surgery, such as the study 
mentioned previously, have shown a lower incidence of visual disturbance with 
larger treatment zones. However, with a patient population of 6 subjects, the data 
obtained in this study may be questionable and larger patient populations would 
allow us to determine whether a decrease in glare is statistically significant. 
Furthermore, time constraints in this study allowed only one month wear times for 
each lens and may not have been an optimal treatment duration. Future 
experiments may consider longer treatment periods, which would allow for more 
reliability and observations to determine whether any symptoms of glare resolve 
over time. 
These considerations for future studies should be investigated in order to 
explore the full effect of optic zone on visual acuity and glare. Promising results 
have been produced from refractive surgery and similar studies in 
orthokeratology can give patients a more viable, non-surgical option to laser eye 
surgery. 
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TABLE I. FINAL UNCORRECTED VISUAL ACUITY ACHIEVED 
(SNELLEN FRACTION) 
Subject 6.0mmOZ(R) 6.0mmOZ(L) 6.7 mm OZ (R) 6.7 mm OZ (L) 
1 20125 20125 20/40 20/40 
2 20/16 20/16 20/16 20116 
3 20120 20116 20/20 20/16 
4 20/20 20/16 20/20 20/20 
5 20/16 20/16 20/16 20116 
6 20/16 20/16 20/16 20/16 
(SNELLEN DECIMALS) 
Subject 6.0mm0Z(R) 6.0mm0Z(L) 6.7 mmOZ(R) 6.7 mm OZ (L) 
1 0.80 0.80 0.50 0.50 
2 1.25 1.25 1.25 1.25 
3 1.00 1.25 1.00 1.25 
4 1.00 1.25 1.00 1.00 
5 1.25 1.25 1.25 1.25 
6 1.25 1.25 1.25 1.25 
Table II. Refractive error change 
Subject Baseline Baseline 6.0 mm Ll SE 6.0mm Ll SE 6.7mm Ll SE 6.7mm Ll SE I 
(R) (L) OZ (R) OZ (L) OZ (R) OZ (L) 
1 -2.75 OS -2.75 OS -0.75- 1.88 -1.00- 1.5 -0.75 OS 2.00 -0.75- 1.75 
0.25x123 0.50x16 0.50x075 
8 
2 -1.50 OS -1.00 OS +1.25 OS 2.75 +1.25 2.25 +0.50- 1.88 +0.75 OS 1.75 
OS 0.25x099 
3 -1.50-1.25 -1.00 OS +0.75- 2.625 +1 .75 2.75 + 1.00- 2.625 +1.00 OS 2.00 
X 100 0.50x100 OS 1.00x1 04 
4 -0.75 OS -0.75 OS +1.50 OS 2.25 +1.00 1.75 +0.75- 1.38 +1.25- 1.75 
0.25x090 0.50x090 
5 -1.25 OS -1.25 OS + 1.00- 1.875 +0.75- 1.625 +1 .25- 2.00 +1.25- 2.1 25 
0.75x105 0.75x09 1.00x1 00 0.75x075 
0 
6 -1.25-0.25 -1.00-0.50 +0.75 OS 2.125 +0.50 1.75 +0.25 OS 1.625 +0.25 OS 1.50 
X 030 X 100 OS 
-- --
L__~ 
Table Ill. Treatment Zone Diameters 
baseline vs. baseline vs. 6.7 mm difference baseline vs. difference 
Subject 6.0 mm_{_R) (Rl baseline vs. 6.0 mm (L) 6.7mm (L) 
1 superior 1.87 2.25 2.3 2.22 
inferior 3.69 4.47 2.25 2.57 
nasal 2.77 3.08 2.15 2.51 
temp 2.8 2.75 2.85 2.75 
avg.tx diam 5.57 6.28 0.71 4.78 5.03 0.25 
2 superior 2.72 2.82 2.9 2.56 
inferior 2.95 2.59 3.06 2.98 
nasal 2.43 2.49 2.55 2.23 
temporal 3.19 2.88 3.14 3.14 
avg.tx.diam 5.65 5.39 -0.26 5.83 5.46 -0.37 
3 superior 2.77 3.69 2.61 2.77 
inferior 2.15 2.22 2.46 2.33 
nasal 1.96 1.46 2.38 2.69 
temporal 3.19 3.29 3.14 3.24 
avg.tx diam. 5.04 5.33 0.29 5.37 5.52 0.15 
4 superior 2.41 1.57 2.43 1.88 
inferior 2.67 2.56 2.72 2.59 
nasal 2.26 2.48 2.05 1.73 
temporal 3.4 3.63 3.63 3.79 
avg.tx diam 5.37 5.12 -0.25 5.42 4.99 -0.43 
5 superior 1.74 1.96 2.25 1.81 
inferior 2.49 2.46 2.57 2.5 
nasal 2.61 2.25 2.72 2.67 
temporal 2.61 2.85 2.57 2.54 
avg. tx diam 4.73 4.76 0.03 5.06 4.76 -0.30 
6 superior 2.36 2.46 2.25 2.2 
inferior 2.33 2.54 0.47 3.06 
nasal 1.94 2.07 2.81 2.3 
temporal 3.66 3.48 3.4 3.23 
av_g.tx.diam 5.15 5.28 0.13 4.47 5.4 0.93 
Total Average 5.25 5.36 0.195 5.16 5.19 
0.162 
--- - '------- --
TABLE IV. SUBJECTIVE GLARE ASSESSMENT 
Subject Pretreatment 6.0mm OZ 6.7 mm OZ 
1 n/a n/a n/a 
2 3.71 2.71 2.14 
3 2.86 1.71 1.57 
4 2.29 1.85 1.85 
5 n/a n/a n/a 
6 1.43 2.71 2.43 
Average 2.57 2.25 2.00 
Figure 1. Final Uncorrected Visual Acuity Achieved 
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Figure 3. Average Treatment Zone Diameter 
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Figure 4. Subjective Glare Assessment 
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